SCIENCE

Mechanism of Action

AB-KOLICARE acts through three main mechanisms to address the root causes of functional gastrointestinal disorders (FGIDs) in infants:

A
Inhibition of pathogenic bacteria
B
Growth of Bifidobacteria
C
Expression of tight junction proteins
D
Production of poly-P
E
Anti-inflammatory activity

Click on spots A to E to discover how AB-KOLICARE interacts with the intestinal wall.

Gut Microbiota Balance

  • Supports the growth of beneficial bifidobacteria, including HRB (Human-Residential Bifidobacteria) like B. longum KABP™ 042, which efficiently digests HMOs to promote a balanced gut microbiota1.
  • Inhibits pathogenic bacteria through the production of organic acids (lactate, acetate) and bacteriocins, reducing harmful groups like Escherichia coli, Klebsiella, and Enterobacter that are often elevated in colicky infants2.
  • Demonstrated significant increases in bifidobacteria populations within 21 days of use, supporting long-term gut health3.

Growth of B. longum KABP®042 with the HMO LNT as unique carbon source

Growth of B. longum KABP®042 with the HMO LNT as unique carbon source

AB-KOLICARE® growth inhibition against pathogens

AB-KOLICARE® growth inhibition against pathogens

Changes in gut bacteria abundance by AB-KOLICARE®

Changes in gut bacteria abundance by AB-KOLICARE®

Modulation of serum cytokine levels by P. pentosaceus KABP®041

Colic and constipation improvement in formula, mixed and breastfed subgroups

Anti-Inflammatory Activity

  • P. pentosaceus KABP™ 041 modulates the immune system, increasing levels of the anti-inflammatory cytokine IL-10 and reducing pro-inflammatory markers like TNF-α, IL-1β, and IL-64.
  • B. longum KABP™ 042 also contributes by producing acetate, a short-chain fatty acid (SCFA) known for its anti-inflammatory properties1.

Synergistic Protection of the Intestinal Barrier

  • Both strains work together to strengthen the intestinal barrier by promoting the expression of tight junction proteins like ZO-1 and CLDN-1, which are critical for maintaining gut integrity2.
  • B. longum KABP™ 042 produces high levels of polyphosphate (poly-P), which further enhances the intestinal barrier by activating protective pathways, including HSP27, reducing permeability and increasing gut resilience1.

Gene expression of tight junction genes after co-culturing with AB-KOLICARE®

Growth of B. longum KABP®042 with the HMO LNT as unique carbon source

See Suporting Clinical Data

References

  1. Alcántara, C. et al. Study of the biosynthesis and functionality of polyphosphate in Bifidobacterium longum KABP042. Scientific Reports 2023 13:1 13, 1–13 (2023).
  2. Astó, E. et al. Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. Front Microbiol 12, (2022).
  3. Santas J, Fuentes MC, Tormo R, Guayta-Escolies R, Lazaro E, C. J. Pediococcus pentosaceus CECT 8330 and bifidobacterium longum CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharma Bio Sci 6, 458–466 (2015).
  4. Dong, F. et al. Pediococcus pentosaceus CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice. J Transl Med 20, 1–16 (2022).